Suppr超能文献

癌细胞如何产生和应对干扰素-I。

How cancer cells make and respond to interferon-I.

机构信息

Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Trends Cancer. 2023 Jan;9(1):83-92. doi: 10.1016/j.trecan.2022.09.003. Epub 2022 Oct 8.

Abstract

Acute exposure of cancer cells to high concentrations of type I interferon (IFN-I) drives growth arrest and apoptosis, whereas chronic exposure to low concentrations provides important prosurvival advantages. Tyrosine-phosphorylated IFN-stimulated gene (ISG) factor 3 (ISGF3) drives acute deleterious responses to IFN-I, whereas unphosphorylated (U-)ISGF3, lacking tyrosine phosphorylation, drives essential constitutive prosurvival mechanisms. Surprisingly, programmed cell death-ligand 1 (PD-L1), often expressed on the surfaces of tumor cells and well recognized for its importance in inactivating cytotoxic T cells, also has important cell-intrinsic protumor activities, including dampening acute responses to cytotoxic high levels of IFN-I and sustaining the expression of the low levels that benefit tumors. More thorough understanding of the newly recognized complex roles of IFN-I in cancer may lead to the identification of novel therapeutic strategies.

摘要

癌细胞急性暴露于高浓度的 I 型干扰素(IFN-I)会导致生长停滞和细胞凋亡,而慢性暴露于低浓度的 IFN-I 则会提供重要的生存优势。酪氨酸磷酸化的干扰素刺激基因(ISG)因子 3(ISGF3)驱动 IFN-I 的急性有害反应,而未磷酸化的(U-)ISGF3 缺乏酪氨酸磷酸化,驱动必需的组成性生存机制。令人惊讶的是,程序性细胞死亡配体 1(PD-L1)经常在肿瘤细胞表面表达,因其在使细胞毒性 T 细胞失活方面的重要性而广为人知,它也具有重要的内在肿瘤促进活性,包括抑制细胞对高浓度细胞毒性 IFN-I 的急性反应,并维持有利于肿瘤的低水平表达。更深入地了解 IFN-I 在癌症中的新发现的复杂作用,可能会导致新的治疗策略的出现。

相似文献

1
How cancer cells make and respond to interferon-I.癌细胞如何产生和应对干扰素-I。
Trends Cancer. 2023 Jan;9(1):83-92. doi: 10.1016/j.trecan.2022.09.003. Epub 2022 Oct 8.

引用本文的文献

本文引用的文献

3
Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?溶瘤病毒与癌症,你了解其主要机制吗?
Front Oncol. 2021 Dec 22;11:761015. doi: 10.3389/fonc.2021.761015. eCollection 2021.
4
Oncolytic Virotherapy: From Bench to Bedside.溶瘤病毒疗法:从实验台到临床应用
Front Cell Dev Biol. 2021 Nov 26;9:790150. doi: 10.3389/fcell.2021.790150. eCollection 2021.
7
Can Biomarkers Guide Oncolytic Virus Immunotherapy?生物标志物能否指导溶瘤病毒免疫疗法?
Clin Cancer Res. 2021 Jun 15;27(12):3278-3279. doi: 10.1158/1078-0432.CCR-21-0660. Epub 2021 Apr 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验